TABLE 1.
Basis parameters of the study participants.
| VNS (n = 5) | SOC (n = 5) | |
|---|---|---|
| Age (in years) | ||
| Mean | 55.6 | 53.2 |
| Min-Max | 42–68 | 43–64 |
| Standard deviation | 8.69 | 7.83 |
| Gender | ||
| 40% female | 60% female | |
| 60% male | 40% male | |
| Comorbidities | ||
| Hypertension | 60% | 40% |
| Obesity | 80% | 80% |
| Mean BMI | 35.32 | 33.22 |
| Diabetes | 40% | 60% |
| Chronic artery disease | 20% | 0% |
| Chronic renal failure | 20% | 0% |
| Chronic lung disease | 0% | 0% |
| Thyroid disease | 0% | 20% |
| Active cancer | 0% | 0% |
| Hematological Disease | 0% | 0% |
| Rheumatological disease | 0% | 20% |
| Current Smoking | 20% | 0% |
| SARS-CoV-2 Vaccination | 0% | 0% |
| Virus variant | 80% B.1.617.2 (Delta) 20% unknown | 100% B.1.617.2 (Delta) |
| Time between symptom onset and ICU admission (in days) | ||
| Mean | 9.60 | 7.80 |
| Min-Max | 7–16 | 5–12 |
| Standard deviation | 3.26 | 2.64 |
| Time between symptom onset and study Inclusion (in days) | ||
| Mean | 10.4 | 8.4 |
| Min-Max | 8–17 | 6–12 |
| Standard deviation | 3.32 | 2.06 |
| Need of non-invasive ventilation at time of study inclusion | 80% | 80% |
| Horowitz Index at time of study inclusion | ||
| Mean | 124.7 | 103.8 |
| Min-Max | 69.8–190.7 | 65.6–180 |
| Standard deviation | 46.95 | 40.81 |
| Length of aVNS (in days) | ||
| Mean | 12 | — |
| Min-Max | 3–18 | — |
| Standard deviation | 6.23 | — |
| Therapy | ||
| Corticosteroids | 100% | 100% |
| Other immunosuppressive agents | 0% | 0% |
| Antimicrobial therapy | 80% | 80% |